Acquiring Company
Acrivon Therapeutics
Acquired Company
Aqilion AB
Description
On November 6, 2026, Acrivon Therapeutics, Inc. announced its acquisition of Aqilion AB's asset programs for the development of oral JAK1 inhibitors and a PKCθ inhibitor preclinical program. This acquisition empowers Acrivon to enhance its therapeutic offerings for the treatment of inflammatory and autoimmune diseases. The agreement includes the complete transfer of relevant assets without additional milestone or royalty payment obligations.
Quick answer
Acrivon Therapeutics is acquiring Aqilion AB, announced November 6, 2026. Acrivon Therapeutics is based in Watertown, Massachusetts, United States.
- How much did Acrivon Therapeutics pay for Aqilion AB?
- The deal value was not disclosed.
- What does Acrivon Therapeutics do?
- Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
- Where are Acrivon Therapeutics and Aqilion AB based?
- Acrivon Therapeutics is based in Watertown, Massachusetts, United States. Aqilion AB is based in Sweden.
- Who are the decision-makers at Acrivon Therapeutics?
- Fundz holds 3 contacts at Acrivon Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- Petauri acquires Franklin Pharmaceutical Consulting (October 8, 2026)
- AmyriAD acquires Recognify Life Sciences for cognition boost (October 7, 2026)
- Gland Pharma acquires 60% stake in Novelstar Pharma (October 5, 2026)
Who to call at Acrivon Therapeutics, and when
When Acrivon Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Acrivon Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acrivon Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acrivon Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acrivon Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aqilion AB?
Aqilion AB was acquired by Acrivon Therapeutics, based in Watertown. The deal was reported on November 6, 2026. Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. Acrivon Therapeutics is publicly traded (ACRV) and operates in Biotechnology.
When did Acrivon Therapeutics acquire Aqilion AB?
Acrivon Therapeutics's acquisition of Aqilion AB was reported on November 6, 2026. On November 6, 2026, Acrivon Therapeutics, Inc. announced its acquisition of Aqilion AB's asset programs for the development of oral JAK1 inhibitors and a PKCθ inhibitor preclinical program. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aqilion AB do?
Aqilion AB is a Swedish public limited company specializing in the development of innovative therapeutics for inflammatory and autoimmune diseases. The company is dedicated to advancing research and development in the field of pharmaceuticals. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.